Regulator waives off clinical trials, clears Sanofi TB drug

November 6, 2019 Gubba Pharma In E News

India’s drug regulator has approved (India)’s new anti-tuberculosis drug rifapentine , waiving local clinical trials in a move to bolster efforts to prevent latent infections from progressing into active TB
“We have recently received final approval for rifapentine from the Indian regulatory authorities. Rifapentine is now officially registered in India,” Thibaud Lefort, Sanofi’s global health business chief, told ET on the sidelines of the 50th Union World Conference of Lung Health in Hyderabad.
While India carries the highest burden of TB with an estimated 2.69 million cases in 2018, more alarming is the possibility of a large pool of people harbouring the ‘silent infection.’ About 40% of the country’s population is estimated to have latent TB infection.
The waiver granted to Sanofi’s rifapentine, which is sold under the brand Priftin, is in the public interest, with a restricted marketing licence to supply the drug only for the government-run national TB programme.
Sanofi is now in talks with the government on the price of the drug, following its decision on Thursday to slash the price by 66%. The agreement brings rifapentine 150 mg tablets down to a price of €4.62/pack of 24 tablets (?364) from €13.60/pack of 24 tablets. Rifapentine is critical in preventing TB from developing and the lower price will benefit over a million people in India, experts said.
“What we need is to finalise the local price. We are in active discussion with the government authorities to finalise the price, taking into account the same discount. We are hopeful that by the first half of 2020 we should see Indian patients receiving rifapentine,” Lefort said.
The company will be required to conduct Phase IV trials in India, conducted after the medicine is made available to help identify any unforeseen side effects on patients. The once-weekly rifapentine 150 mg pills are found to be effective in cutting short the TB drug regimen by three months. Previously, preventive TB therapy took six to 36 months. A rifapentine-based regimen shortens the treatment to 12 weekly doses.
According to the latest World Health Organisation report, TB is the leading cause of death from infectious disease worldwide, killing 1.5 million people a year.

Source : economictimes.indiatimes

About the author

Gubba Group:


Plot no-118-A, Five Star Industrial Area, MIDC, Shendra, Aurangabad.


Survey No.271,Muppireddypalli (Village),Toopran Mandal, Medak District, Hyderabad,Telangana


Survey No.255, Kandlakoya Village, Medchal R R Dist, Hyderabad,Telangana


Plot No. 101 & 103 IDA Medchal R R District, Hyderabad,Telangana


Plot No. 101 & 103 IDA Medchal R R District, Hyderabad,Telangana

Survey No. 46, Mediciti Hospital, Rajbollaram (village),Medchal R R Dist, Hyderabad,Telangana

Survey No.741 Lalgadi Malakpet VillageShameerpet Mandal, R R Dist, Hyderabad,Telangana

Plot : C-8/2a, Industrial Area, Uppal, Hyderabad,Telangana

Plot No.1, Survey No.85/A, Yellampet, Medchal R R Dist, Hyderabad,Telangana

Plot No.2 Survey No.85/A, Yellampet, Medchal R R Dist, Hyderabad,Telangana

Survey No.150&151, Athavelli village, Medchal R R Dist, Hyderabad,Telangana

Survey No.150&151, Athavelli village, Medchal R R Dist, Hyderabad,Telangana

Survey No : 84 C & G, Yellampet Village, Medchal Mandal, R.R Dist, Hyderabad,Telangana


MCJR+C4 Nutankal, Telangana


Banda Mailaram, Telangana 502336


Plot : C-8/2a, Industrial Area, Uppal, Hyderabad,Telangana


Aanaram, Telangana 500043


Kothur Village, Telangana 502279


Visakhapatnam, Andhra Pradesh 530012


Surat, Gujarat 396430


Gundlapochampally, Telangana 500014


MEDCHAL, NEAR ELECTRICAL OFFICE, 501401 R R DIST. Hyderabad


Hyderabad, Telangana 501401


Siddipet, Telangana 502279


Medchal Mandal, Hyderabad, Telangana 501401


Nizamabad, Telangana 503230


IDA, Medchal, 501401